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NOMEMCLATURE 
HSA   Human Serum Albumin 
BSA    Bovine Serum Albumin 
TFE    1- (9-anthryl) - 2, 2, 2- triflouroethanol 
BNA    1, 1′-Binaphthyl-2, 2′-diamine 
HOMO   Highest Molecular Orbital 
LUMO   Lowest Molecular Orbital 
FS    Fluorescent Substance 
QA    Quenching Agent 
IR    Infrared Spectroscopy 
FTIR    Fourier Transform Infrared Spectroscopy 
NMR    Nuclear Magnetic Resonance 
TA    Tartaric Acid 
PAH    Polycyclic Aromatic Hydrocarbons 
CEP    Chiral Environmental Contaminant 
ER    Estrogen Receptor 
PR    Progesterone Receptor 
HER2    Human Epidermal Growth Factor 2 
TN    Triple Negative 
g    gram 
nm    nanometer 
mL    millimeter  
M    molar 
PBS    phosphate buffered saline 
DNA    deoxyribonucleic acid 
MOPS   morpholine propane sulfonic acid 
A    angstrom 
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 ABSTRACT 
The negative health impact of chiral environmental pollutants (CEPs), including mutagenicity, 
teratogenicity, and developmental problems, highlight the importance of chirality to the 
biomedical research community and the need for new techniques for accurate analysis of CEPs 
in humans to promote the development of biomedical protocols for CEPs poisoning therapy. This 
study examined the effects of chirality on 1-(9-anthryl)-2,2,2-triflouroethanol (TFE) and 
1,1′binaphthyl-2,2′-diamine (BNA) enantiomers interactions with human serum albumin (HSA), 
the dominant serum protein and a transporter of hormones, drugs and metabolites in human. 
Specifically, the emission, the binding constants, stoichiometry, and thermodynamic properties 
of enantiomers of TFE-HSA and BNA-HSA complexes were investigated using analytical 
spectroscopy (Fourier transform infrared, UV-visible and fluorescence). The influence of 
experimental conditions such as the temperature and the concentration of TFE and BNA 
enantiomers on TFE-HSA and BNA-HSA complexations were also investigated. In addition, the 
effect of TFE and BNA enantiomers on the mobility of HSA in solution was explored by the use 
of steady state fluorescence anisotropy measurement. Furthermore, enantiomeric cytotoxicity 
and cell viability of TFE and BNA enantiomers on triple negative breast cancer cells was 
investigated. The results of this study showed considerable differences in the emission property, 
the binding constants, and thermodynamic properties of the enantiomers TFE-HSA and BNA-
HSA complexes, indicating diastereomeric complex formations and chiral discrimination. The 
result of the study also showed differences in the TFE and BNA enantiomeric cell cytotoxicity 
and cell viability on triple negative breast cancer cells.  
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CHAPTER 1 
INTRODUCTION 
1.1 Chirality 
1.1.1 Background 
The developments of stereochemistry and molecular chirality can be dedicated to the 
work of French scientists Jean Biot and Louis Pasteur over 190 years ago.1,2 Biot was the first to 
report on chirality of a molecule and paved the way for Louis Pasteur. Pasteur began his 
investigations on crystallography of tartaric acid (TA) and at the young age of twenty-five, he 
later gave his memoir on the discovery to the Academy of Sciences in Paris in 1848. Pasteur 
noted that from his crystal cleavage observations, a crystal of each constituent space filling 
molecule are images of each other in overall shape. Below is Pasteur original drawing of the two 
crystals. 
 
 
Figure 1. Pasteur’s Original Drawing of TA Crystal structure 2 
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Although the term chirality was not used until 1894 by Sir William Thomas, chirality is 
said to be derived from the Greek word “kheir” meaning hand. Chirality is now formally defined 
as the geometric property of an object of not being superimposable with its mirror image.2 
Simplistically, chirality refers to spatial arrangement but more specifically, it explains the ability 
of a molecule to exist in two or more forms but neither form is able to be superimposed on its 
mirror image. A chiral molecule is therefore said to not have a plane of symmetry (Figure 3), not 
have an inversion center, have a non-superimposed mirror image and have at least one chiral 
center (Figure 2).When a molecule can be superimposed on its mirror image it is said to be 
achiral (the opposite of chiral).  
 
OH CF3
                                                     
OH CF3
 
                                     A                                                                                            B 
Figure 2. (S)-(+)-1-(9-Anthryl)-2,2,2-trifluoroethanol and  (R)-(−)-1-(9-Anthryl)-2,2,2-
trifluoroethanol 
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                             A                                                                                    B 
Figure 3. (R)-(+)-1,1′-binaphthyl-2,2′-diamine and (S)-(-)-1,1′-binaphthyl-2,2′-diamine 
 
In 1874, Jacobus Henricus Van't Hoff and Joseph Le Bel reported that the tetrahedral 
arrangement of the carbon that were bound to different groups in ammonium tartrate made the 
entire molecule asymmetric in structure. The resulting carbon atom is said to be the asymmetric 
or the chiral center.3 
1.1.2 The Language of Chirality 
Pasteur gave birth to the oldest terminology in molecular chirality. He gave the name 
dissymmetry to describe this phenomenon of left and right handedness in molecules. Over the 
next 50 plus years the evolution in terminology of molecular chirality was contributed to many 
scientist. In 1874, Jacobus Henricus Van’t Hoff discovered what he called the asymmetric 
carbon atom. In 1886 the German chemist Aemilius Wunderlich introduced configuration and, in 
1889 German chemist, Viktor Meyer coined stereochemistry. The terms chirality and chiral were 
introduced in 1894 by the British physicist Sir William Thomson while the base word “enantio” 
used in words such as enantiomer, enantiomorph and enantioselective was introduced in 1856 by 
the German crystallographer Carl Friedrich Naumann.2  
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Enantiomer is the term used to describe chiral molecules with noon superimposable 
mirror images. After Pasteur’s manual separation of the two tartaric acid crystals, he observed 
that linearly polarized light was affected differently by the enantiomers. He found the rotations to 
be equal in absolute magnitude but opposite in their direction. This observation of light led to the 
D/L convention method of naming enantiomers. When polarized light interacts with an 
enantiomer it undergoes an optical rotation. If an enantiomer rotates the light to the right it is 
termed dextro- rotary and denoted with a + sign.4 If the enantiomer rotates the light to the left it 
is termed levo-rotary and denoted with a – sign. A racemic mixture is indicated by a (±) sign 
meaning there is a 1:1 enantiomer mixture. In order for scientist to understand the absolute 
configuration of the molecule, another naming system was established, the R/S system.  Once the 
structure has been determined the substituting atoms that are bound to the chiral carbon are 
numbered in order of priority with respect to their atomic number. The higher atomic number 
gaining the highest priority. The molecule is then viewed opposite to the lowest group and if the 
order of the groups are in a clockwise direction it’s assigned the R configuration. If the order of 
the groups are in a counter clockwise direction it’s assigned the S configuration. 
 
Figure 4. Depiction of R/S Naming Configuration 
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1.1.3 Chirality in Drug Design 
The phenomenon of chirality discovered in 1984 has now developed into its own sub 
discipline of chemistry known as stereochemistry where the study of spatial arrangement of 
atoms in a molecule and their manipulation is analyzed. Pasteur’s contributions to chirality did 
not end with stereochemistry. After his research shifted Pasture discovered biological 
enantioselectivity in 1857 when he noticed that the enantiomers of TA were being metabolized at 
different rates by the same microorganism. It wasn’t until 30 years later that the first report on 
enantioselectivity at a biological receptor was made. Italian scientist Arnaldo Piutti was 
responsible for this noted phenomenon back in 1886. A receptor is a molecule that can receive 
chemical signals coming from outside of the cell. Piutti’s discovery of enantioselectivity was due 
to the taste of asparagine. Piutti noticed there was a difference in taste between the pure D-
asparagine (sweet taste) and the L-asparagine (tasteless). This was the first indication of a 
biological receptor (sweet receptor) showing enantioselectivity.  
 
NH2
OH
O
O NH2
           
NH2
OH
O
ONH2
 
L - Asparagine                                                   D - Asparagine 
Figure 5. D- and L- Asparagine 
Centuries later Piutt’s discovery still is of great interest when it comes to the chemical 
and biological aspects of molecular chirality. Molecular chirality plays a huge importance in 
pharmacotherapy and the development of new drugs primarily because chiral molecules are the 
major ingredient to many therapeutic agents. In 1987 a Swedish manual of drugs in clinical use 
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were surveyed and 53% were said to have contained a minimum of one stereogenic center and 
out of that 53% that contain a chiral carbon 49% were racemic and 51% were in use as single 
enantiomeric form.2,5 
As Piutt demonstrated enantiomers possess identical, physical and chemical properties. 
However in the presence of other chiral systems these properties can be significantly different. 
The proteins that make up our biological system are large complex chiral molecules resulting in 
the significance chirality plays in drug design and development. The process of drug action or 
delivery requires a chemical interaction between the enantiomer of a drug and a biological 
receptor.  The bonding interactions between a drug and a receptor is dependent on functionalities 
associated with the drug and the binding sites on the receptor. In the case of enantiomers, spatial 
arrangement is one of these dependent functionalities. An example of the significance of spatial 
arrangement is illustrated below.  
 
Figure 6. Schematic Representation of  Enantiomers of a Chiral Molecule Receptor6 
 
The ability of one enantiomer to “fit” into the binding site of a receptor may not produce 
identical binding energy or reaction thus resulting in on enantiomer being more favorable or 
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having a higher affinity. When two enantiomers of a chiral drug are in the presence of a chiral 
receptor (biological system) the difference between the reactions can be beneficial, ineffectual or 
even destructive.6 
An example would be the Thalidomide episode of 1957 when a German pharmaceutical 
company introduced a new drug to the market. The drug was intended to be a sedative to relieve 
morning sickness in pregnant woman. This drug contains one chiral center making it a chiral 
molecule and the drug was marketed as a racemic mixture. After thousands of children were born 
with abnormal body parts and limbs missing scientist discovered that while the (+)(R)-
thalidomide is a sedative the (-)(S)-thalidomide is a teratogen.7 
N
N
O
O
O O H
H
*
                           
N
N
O
O
OOH
H
*
 
(+) (R)-thalidomide                                                  (-) (S)-thalidomide 
Figure 7. R- and S- Thalidomide 
 
It wasn’t until 1992 when the Federal Drug Association recognized the importance that 
chirality play in the development of drug design and began to initiate strict guidelines on chiral 
drugs. Pharmaceutical companies are now required to evaluate the toxicity and actions of 
enantiomers as two separate drugs.  
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1.2 Human Serum Albumin (HSA) 
1.2.1 Function of HSA  
Human Serum Albumin is one of the most widely noted proteins with research dating 
back over 160 years. This large globular protein is synthesized in the liver and accountable for 
60 percent of the total proteins found in the human blood.8 Human serum albumin has a 
circulating blood concentration of about 6mM. As the most abundant protein, HSA has the 
responsibility of maintaining osmotic pressure and being the major transporter of many drugs, 
fatty acids, metals and ligands both exogenous and endogenous. The large abundance of HSA is 
one of the major reasons why this protein is used to study the pharmacokinetic behavior of many 
drugs.9 
1.2.2 Structure of HSA 
Human serum albumin is a single chained macromolecule that is comprised of 585 amino 
acids: Lys59, His16, Arg24, Asp53, Thr28, Ser24, Glu82, Pro24, Gly12, Ala62, Cys35, Val41, Met6, Ile8, 
Tyr18, Phe31, and Trp1 which contribute to its total molecular weight of 66.5kDa.
9,10 
Crystallography studies reveal that this albumin is 67% alpha helix, 10% beta turn, and 23% 
extended chain and folded into a heart shaped molecule with an average thickness of 30 
angstrom.  
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Figure 8. Crystal Structure of Human Serum Albumin6 
Human Serum Albumin is formed into three different but structurally similar domains; 
Domain 1, 2, and 3. Each has two subdomains denoted as A and B. Structural studies have been 
done to help map out binding site specificity.11   There are two reported principle drug binding 
sites located in the subdomains A of domain 2 and 3. These sites are known as Sudlow’s Site 1 
and 2, respectively. Site 1 is described as being a large hydrophobic cavity with the entrance to 
the cavity being surrounded with positively charged residues such as Lys, His and Arg that can 
interact electrostatically with ligands while the inside wall is reported to be occupied by 
hydrophobic side chains. Typical ligands for this domain are reported to be dicarboxylic acids 
and bulky heterocyclic molecules. Literature notes that this site must be large because it has been 
reported to bind ligands as large as bilirubin.6 Site 2 is described as a hydrophobic T shaped 
cavity with two entrances. Both entrances interact with the carboxylic groups on bound ligands. 
11 
 
 
 Figure 9. Complete amino acid sequence of HSA10 
1.2.3 HSA Intrinsic Fluorescence 
Human serum albumin contains three aromatic amino acid residues that can lead to its 
natural fluorescence (tryptophan, tyrosine, and phenylalanine). Each of the three residue have 
distinct absorption and emission wavelength and differ significantly in their quantum yields and 
lifetimes. Tryptophan residues emit a much stronger fluorescence and has a higher quantum yield 
in comparison to tyrosine and phenylalanine. Typical absorption and fluorescence values are 
shown in a chart below. The intensity, quantum yield, maximum fluorescence and wavelength of 
tryptophan residues are solvent dependent. When the tryptophan residue is in the presence of a 
polar solvent the fluorescence shifts to shorter wavelength while inversely the fluorescence 
intensity increases. Tryptophan residues that are reported to be buried in hydrophobic cavities 
have shifted spectra as opposed to residues found on a proteins surface.  
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Table 1.  
Absorption and Fluorescence parameters of intrinsic amino acids 
                                 
                                     
Lifetime 
                                          
(ns) 
Absorption Fluorescence 
Wavelength 
(nm) 
Molar 
Absorptivity 
(M
−1
 cm
−1) 
Wavelength 
(nm) 
Quantum 
Tryptophan 2.6 280 5600 348 .20 
Tyrosine 3.6 274 1400 303 .14 
Phenylalanine 6.4 257 200 282 .04 
 
The lone tryptophan residue located in Sudlow’s site 1 of the protein is responsible for its 
intense fluorescent emission shifted to 334nm. Tryptophan is an amino acid, aromatic in 
structure which makes it highly fluorescent. With many natural biological species containing 
tryptophan its change in fluorescence can be used to study protein folding, binding to substrates 
and its overall structure. 
1.3 Chiral Molecules of Interest  
1.3.1 Polycyclic Aromatic Hydrocarbons (PAH) 
Polycyclic aromatic hydrocarbons are fused aromatic rings arranged in various isomeric 
configurations and are their own class environmental contaminants. Polycyclic aromatic 
hydrocarbons are in fact the largest class known for their mutagenic and carcinogenic behavior. 
PAH’s occur in the environment predominantly from the incomplete combustion of organic 
substances. Many environmental sources of PAH’s include air pollution from industrial sites, 
motor vehicle air pollution, smoke from cigarettes and our diet. Humans can be exposed to 
PAH’s through skin contact, breathing in air, eating or drinking of contaminated food or water. 
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Unfortunately human exposure to even nanogram quantities of PAHs on a daily basis is 
unpreventable due to its large abundance in the environment. 
The ubiquity of PAH’s were made evident by their detection in sediments, air, soil, 
surface waters, drinking water, industrial effluents, plant and animal tissues. PAH’S are 
comprised of two or more fused aromatic rings consisting of hydrogen and carbon atoms in 
linear, angular or cluster arrangements. Some PAH’s may have substituents attached to one or 
more rings. The PAH’s that have substituents may sometimes exhibit greater toxicological 
effects than the parent compound. PAH’s with molecular weight ranging from 128.16 
(naphthalene) to 300.36 (coronene) are environmental concerns due to their mobility. PAH’s 
with high molecular weight are immobile with extremely low volatility and solubility. 
1.3.2 Chiral Environmental Pollutants (CEPS)  
The health, growth and longevity of the human race and of all other organism depend 
heavily on the quality of the environment. Thus, protection and preservation of the environment 
is essential and with current industrialization and the increasing developments in the world 
pollution is a crucial problem.12 Proper monitoring of these pollutants is both necessary and 
important for the health of all populations. Numerous reports have been published indicating 
how chiral environmental pollutants can cause harmful effects to the human reproductive system. 
Among various environmental pollutants, PAH’s are the most toxic due to their carcinogenic, 
teratogenic, and mutagenic nature.13 Some PAH derivatives are chiral toxic pollutants. 
Additionally some non-chiral pollutants degrade into the environment and their degradation 
products are toxic and chiral in nature.14 There have been reports on the analysis of organic 
pollutants but these reports do not distinguish between enantiomers of chiral pollutants as 
separate pollutants.  
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1.4 Breast Cancer 
1.4.1 Background 
Cancer is a global disease that has been the result of millions of deaths dating back to the 
ancient Egyptian times.15 Cancer is a disease characterized by uncontrollable growth, spread and 
accumulation of abnormal cells.15 Abnormal cells can become cancerous when the damage is 
done to DNA. The cells are unable to repair the damage and unlike normal cells, the abnormal 
cells do not die off. Cancer is always named after the tissue it originates from meaning cancer 
may spread to other organs in the body however if it originated in the breast it is still termed 
breast cancer. Exceeded only by lung cancer, breast cancer is the second leading cause of cancer 
deaths among American women.16 Twelve percent of women in the US will develop breast 
cancer in their lifetime and the American Cancer Society estimates that in the following year 
there will be 231,840 new cancer cases and of those 40,290 will result in death.16 Breast cancer is 
a type of malignant tumor, meaning it has the ability to invade and metastasize to different areas 
of the body. Breast cancer is categorized into different stages that depend on the size and 
development of the tumor thus treatment options vary depending on the type and stage of the 
cancer. Radiation, chemotherapy, hormone therapy and drug-targeted therapy is given to stop the 
growth of breast cancer cells. Hormone therapy is used in estrogen (ER), progesterone (PR) and 
human epidermal growth factor 2 receptor (HER2) positive cancers. This treatment is used to 
stop the growth of cancer cells and is successful for 2 out of 3 breast cancers.  
1.4.2 Triple Negative Breast Cancer 
Triple negative breast cancer (TNBC) is an aggressive type of breast cancer that accounts 
for 10-20 percent of the breast cancer cases amongst American women.16 TNBC is PR, ER and 
HER2 negative and therefore hormone therapy given to other breast cancer patients is ineffective 
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in patients with TNBC. Although TNBC can be detected in all ethnic groups it is more 
commonly found in younger African American and Latino women, and women who carry the 
BRCA1 mutation. Research has shown that despite TN breast cancer negative response to 
hormone therapy, it responds well to chemotherapy in comparison to breast cancer that is 
hormone therapy positive.  
1.4.3 Cell Viability Assay and Cell Death 
Chiral polycyclic aromatic hydrocarbons are found to be very toxic and are impossible to 
eliminate from human exposure. It is essential to study the inherent cytotoxicity that may be 
associated with these chiral contaminants.  Cell viability assays are often used to determine if the 
test analyte will have any effects on cell proliferation or show harmful effects that lead to cell 
death. Tyrphan blue dye exclusion is widely used to determine the number of viable cells present 
in a cell suspension. The mechanism of the dye is based on the theory that cells with an intact 
membrane are selective in what they let pass through where as a cells whose membrane is not 
intact (dead) will not be selective and uptake the dye. Therefore all the cells that are stained are 
considered dead cells. Cells that exclude the dye are viable making tryphan blue a vital stain 
allowing discriminator between viable and dead cells.  
1.5 Fluorescence Spectroscopy 
1.5.1 Fluorescence Theory  
Since its first observation in 1565 by Monardes, fluorescence spectroscopy has evolved 
into a robust and sensitive analytical tool, finding use in all areas of chemistry ranging from 
biological to physical applications.17,18 Photoluminescence falls under a larger umbrella called 
luminescence spectroscopy and is named with regard to its mode of luminescence. 
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Luminescence involves an electron(s) being promoted from its ground level to a higher energy 
level. As the electron(s) returns to its ground level energy is given off in the form of light. 
Specifically fluorescence is one of two types of photoluminescence defined as the reemission of 
energy in the form of light by a substance that has absorbed outside electromagnetic radiation at 
a specific wavelength (usually ultraviolet).19,20  Once G.G. Stokes termed the word 
“fluorescence” he identified the difference between fluorescence and phosphorescence by the 
duration of emission after excitation of the species. However, there was not a solid distinction 
between the two types of photoluminescence (fluorescence and phosphorescence). It was not 
until 1929 when Francis Perrin made a sufficient distinction between the two. In the case of 
fluorescence spin multiplicity remains while in phosphorescence the spin multiplicity is changed 
from a singlet to a doublet or vice versa.19 Figure 1 shows the distinction by the Jablonski 
diagram where S0 and S1 represent the ground and first electronic state.
    
 
 
Figure 10. Simplified Jabonski diagram 
A substance that is able to absorb light was termed a fluorophore. R. Meyer Stokes noted 
that the resulting emission of light is emitted at a longer but equal in magnitude wavelength than 
that of its absorption.20 The amount of energy emitted and the wavelength upon emission are 
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extensive properties that are specific to the fluorophore and its surrounding. When a fluorophore 
is exposed to electromagnetic radiation with a specific wavelength the electrons with 
corresponding energy will experience a change to its electronic transitions.21,22 Those electrons 
absorb the energy and are promoted to a level of higher energy. This promotion of electrons is 
favored when moving from the highest occupied orbital (HOMO) to the lowest unoccupied 
orbital (LUMO). The molecules will finally relax to its lowest vibrational level and emit energy 
in the form of light. The time from a molecule reaching excited state to relaxing back to its 
ground state is called its life time (τ) and is around 10ns for typical fluorophores.23  
Absorption of a fluorophore can be used interchangeably with excitation in terms of 
fluorescence spectroscopy. Absorption is a term to describe the intake of energy by a florophore. 
In a more precise termonolgy absorption occurs when changes in matter are actived by an 
oscillating electromagnetic field of a specific frequency. When that frequecy is close to the 
frequency associated with the activated electronic dipoles of the matter absorption occurs, 
denoting why the excitation and emmission of a florophore is an extensive variable. 
1.5.2 Flourescence Quenching 
  Another observation Stokes made was the reduction of flourescence intensity upon the 
addition of NaCl to quinine in 1852.18,23 Quenching as it is now known is any process that causes 
reduction in the intensity of flourescence. A quencher is any molecule that is responsible for the 
reduction in intesity. Quenching measurement can be a reliable tool to measure the assessibility 
of a protein and to examine the binding rates and molar ratios. The majority of the research on 
quenching was not observed until later years.24,25 
However Robert Boyle noticed a phenomenon he called “self-quenching” or 
“concentration-quenching” where he noticed quenching in a molecule due to too many molecules 
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of the substance itself.20 Other quenching mehanisms include dynamic quenching (collision 
between the fluorescent substance and the quenching agent), static quenching (a complex being 
formed between the flourescence substance (FA) and the quenching agent (QA) before excitation 
occurs) and resonance energy transfer (energy from an excied state is transferred to another 
molecule).21,22   
 
FS + QA ↔ COMPLEX ................................................................................................... Equation 1 
 
Static quenching studies are efficient in determining the binding interactions and 
stochiometry between large proteins and smaller molecules. The fluorescence quenching of 
proteins can be induced by static or dynamic quenching and can be determined based upon its 
quenching constant (kq). Dynamic quenching can only have a maximum kq value of  2.0 x 10
10 
M-1s-1, where kq is greater then this mechanism is an indication of static quenching.
22 Dynamic 
quenching constants are determined using the Stern-Volmer equation (Equation 2).26 
𝐹0
𝐹
 = 1+ KSV[QA] .............................................................................................................. Equation 2 
 
[QA] is the concentration of the quenching agent, F0 and F are the fluorescence 
intensities of a fluorphore (in this case the protein) in the absence and presence of a quenching 
agent respectively. Ksv is the Stern-Volmer quenching constant where its significance is 
dependent upon type of quenching. For dynamic quenching Ksv is related to the lifetime (τ0) and 
the bimolecular quenching constant (Kq) of the protein by equation 3.  
Ksv = Kqτ0 .................................................................................................................................................................................. Equation 3 
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However static quenching is given by the following equation;  
 
Ksv = Ka = 
[𝐹𝑆−𝑄𝐴]
[𝐹𝑆] [𝑄𝐴]
 .............................................................................................................................................................. Equation 4 
 
Where FS-QA is the concentration of complex, FS is the concentration of the intrinsic 
fluorescence substance and QA is the concentration of the quenching agent. In the case for static 
quenching its Ksv value is its binding constant. When smaller molecues bind to large proteins 
equivelantly as a result of static quenching a modifed Stern-Volmer equation is used to 
determine binding constants and stoichiometry between the protein and the smaller molecule.27  
log(
𝐹0−𝐹
𝐹
) = log Ka + nlog [QA] ...................................................................................... Equation 5 
 
Where F0 is the fluorescence intensity in the absence of a quenching agent and F is the 
fluorescence intensity after the addition of our quenching agent. When a plot of log [QA] is 
made against the log of the change in fluorescence intensity. Linear regression can be used to 
calculate the Ka (binding constant) and the n (molar ratio) between the free and bound molecules. 
1.5.3 Spectrofluorometer 
Fluorescence studies are examined using a spectrofluorometer. A sample is excited by a 
beam of light which then passes through a monochromator which ensures a single wavelength is 
chosen. As mentioned earlier fluorescence is the resulting emission after excitation, therfore the 
detector is arranged at a 90 degree angle to collect emisson independent from the excitation.             
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Figure 11. Schematic representaion of a Fluorescence Spectrophotometer 
 
The resulting emission is analyzed by a sensor and is read out on a computer. 
Fluorescence spectroscopy is superior in terms of absorbance based techniques because it can be 
measured directly. This leads to its high selectivity and sensitivity. 28 
1.6 Fluorescence Anisotropy 
Fluorescence anisotropy measurements are effectively used in the biomedical industry. 
Anisotropy measurements can be used to obtain information about molecular structure, binding, 
size, motion and to recognize chiral selectivity between an analyte and a chiral selector.29,30,31   In 
fact, the first fluorescence anisotropy was first used to investigate the binding of small molecules 
to proteins in 1953. Fluorescence anisotropy methods are accomplished by applying the 
relationship between the polarization of light used to excite a sample and the subsequent 
polarized light detected from fluorescence.29 In order to fully understand the theory behind 
fluorescence anisotropy a firm understanding of polarized light must be had. 
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1.6.1 Polarization 
 Light is made up of electric and magnetic waves (electromagnetic) that are oscillating in 
different directions. When scientist speak of the “polarization” of light it refers specifically to the 
electric field. The electric field is oscillating in different directions perpendicular to the direction 
of propagation. Polarization of light is the transformation of the electric field in different 
directions to a single direction. A Polaroid filter is used to polarize unpolarized light. The filter is 
made of a material that can block electromagnetic waves of a particular direction. (Schematic 
shown below) 
 
Figure 12. Simplified depiction of a polarized light 
When polarized light is used to excite a fluorescence molecule the emission given off is 
also polarized.  The fluorophores that have absorption transition moments oriented parallel to the 
vector of the polarized light will be excited leading to the excited population to be partially 
oriented.32 
1.6.2 Steady State Anisotropy Measurements 
Steady state fluorescence anisotropy measurements are calculated by the following equation: 
r = 
𝐼𝑣𝑣−𝐼𝑣ℎ
𝐼𝑣𝑣+2𝐼𝑣ℎ
 ........................................................................................................................ Equation 6 
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Where Ivv and Ivh is the intensity of vertical polarized light and horizontally polarized 
light when excited by vertically polarized light respectively. Figure 13 is a schematic diagram for 
L- shaped anisotropy measurements. The sample is excited with vertically polarized light while 
the electric vector of the excitation light is aligned parallel to the z-axis. A separate polarizer is 
placed to measure the intensity of the emission. When this polarizer is aligned parallel to that of 
the excitation emission the intensity is called Ivv. When this polarizer is aligned perpendicular to 
that of the excitation emission the intensity is called Ivh.
33,34 
 
Figure 13. Schematic representaion of Fluorescence Anisotropy Experiment Measurements 
 
When incorporating polarized light with a fluorimeter there may be variations in the 
transmission of vertical and horizontal emissions due to sensitivity of detection systems.31 This 
error can be accounted for by producing G which is the instrumental correction factor. The G 
factor as it is known is the ratio of vertically polarized light to horizontally polarized light using 
horizontally excited polarized light.30 
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G = 
𝐼ℎ𝑣
𝐼ℎℎ
 .............................................................................................................................. Equation 7 
 
The G factor accounts for the deficiencies in optical measurements thus this factor is 
dependent on the slits, filters and wavelengths used.34 Assuming the experimental conditions 
remain unchanged, the G factor need only be calculated once. After the incorporation of the G 
factor the final anisotropy equation comes out to be as followed; 
r = 
𝐼𝑣𝑣−𝐺𝐼𝑣ℎ
𝐼𝑣𝑣+𝐺2𝐼𝑣ℎ
 ...................................................................................................................... Equation 8 
Based off the final anisotropy equation, the values of anisotropy can range from are 0 to 
1. The smaller anisotropy value corresponds to faster motion while higher values correspond to 
slower motion. 
1.6.3 Depolarization 
  Rotational diffusion is the main cause of depolarization in fluid environments and causes 
changes in the direction of the transition moments.30 Fluorescence anisotropy measurements 
unveil the angular displacement of the fluorophore from time of absorption to subsequent 
emission. With fluorescence anisotropy being dependent on fluorophores motions these 
measurements have been widely used for clinical chemistry, to quantify protein denaturation and 
to measure the dynamics of proteins.29 Those fluorophores excited have the ability to rotate in 
different directions causing a decrease in polarization emission.32 
When a large molecule becomes bound to a smaller molecule the change in rotation is the 
main cause of fluorescence depolarization while in its excited state. Thus a measurement of 
fluorescence polarization can be used to diagnose the mobility of our fluorophore bound and 
unbound. Fluorescence anisotropy is a simple one step method for binding assays because it can 
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be performed directly and theoretically once there is a change in molecular weight sequentially 
there will be a change in anisotropy. 30 
1.7 Infrared Spectroscopy 
1.7.1 Theory of Infrared Spectroscopy 
Infared spectroscopy (IR) is a powerful tool for organic chemist to gather information 
pertaining to the structure and for analytical chemist to assess the purity of a compound.35 
Infrared spectroscopy utulizes the fact that molecules absorb in the infrared region (between the 
visible and microwave region of the electromagnetic spectrum). The IR region can be grouped 
into three sub regions: near IR (1400-4000cm-1), mid IR (4000-400cm-1) and far IR (400-10cm-
1). The region of our research interest is the mid IR region because this region corresponds to 
changes in vibrational energy. Infarared spectroscopy is based on the principle that molecules 
have specific frequencies at which they rotate or vibrate in accordance to their vibrational modes. 
All nonlinear molecules with N atoms have 3n degree of freedom. Six of which are vibrational. 
These vibational modes can absorb infrared energy at different frequencies depending on the 
type of bond and the atoms involved. However in order for a vibrational mode in a molecule to 
be active it must be associated with changes in the existing dipole moment. For complex 
molecules five “normal” vibrational modes exist: rocking, wagging, stretching, scissoring, and 
twisting. 
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Figure 14. Types of molecular vibrations 
1.7.2 Fourier Transform Infrared Spectroscopy 
  A Fourier transform infrared spectrometer is comprised of moving mirrors, fixed mirrors 
and beam splitters. The IR light split into two beams. One is reflected off the fixed mirror while 
the other is reflected off the moving mirror. The two beams are reunited at the beam splitter to 
produce an interferogram (pattern formed by wave interference). The light from the 
interferogram is passed through a sample where some light is absorbed and some light is 
transmitted through the sample. The light then reaches the detector and the spectrum is obtained. 
Analysis of the transmitted light discloses the amount of energy absorbed at each wavelength. 
Infrared spectroscopy is used to obtain information about the chemical bonding and molecular 
structure. The spectrum that’s obtained is in essence a molecular fingerprint of the sample taken.  
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1.7.3 FTIR for Protein Analysis 
FTIR technique has been extensively used to investigate the structure and structural 
changes of proteins.25 Contrasting to nuclear magnetic resonance and X-ray crystallography 
which gives information about the tertiary structure of proteins, FTIR reveals the secondary 
structure of proteins. Bands that are characteristic to all proteins include amide 1 and amide 2. 
The amide 1 and 2 bands are a result of carbonyl stretching and N-H bending in peptide bonds.37 
This research utilizes FTIR because it has been proven as a powerful tool for studying the 
structural changes in proteins due to its high sensitivity, low cost and speed.  
1.8 Purpose of Study 
It is impossible for the human system to avoid CEPs completely and since most CEPs are 
found in the environment as racemic mixtures we are exposed to all enantiomers of that 
contaminant.  Once CEPs are absorbed into the human body, HSA is its main depot and carrier 
protein. Earlier stated enantiomers can have different properties upon interaction thus the 
purpose of this study is to distinguish a clear enantiomeric discrimination between (S)-(+)-1-(9-
Anthryl)-2,2,2-trifluoroethanol and (R)-(-)-1-(9-Anthryl)-2,2,2-trifluoroethanol (a commonly 
used enantiomeric solvent for NMR spectroscopy) also (S)-(−)-1,1′-Binaphthyl-2,2′-diamine and 
(R)-(+)-1,1′-Binaphthyl-2,2′-diamine (commonly used chiral ligands for transition metal 
catalysts) in the presence of  HSA. These compounds are ideal in that they are PAH based in 
structure but have functional groups that make then chiral in structure. I will also explore the 
natural rotation, rotational diffusion upon binding, temporal effects to potentially understand its 
mode of binding and the uptake of these contaminants in Triple Negative Breast Cancer cells. It 
is hypothesized that there will be a clear bias between binding constants, thermodynamic 
parameters and anisotropy measurements between the two enantiomers. 
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CHAPTER 2  
EXPERIMENTAL METHODS 
2.1 Solution Preparation  
2.1.1 Materials 
All chemicals used were of analytical standard. (R) 1—(9-Anthryl)-2,2,2- 
trifluoroethanol (≥98%, anhydrous), (S) 1—(9-Anthryl)-2,2,2- trifluoroethanol (≥98%, 
anhydrous), (R)-(+)-1,1′-binaphthyl-2,2′-diamine (≥98%, anhydrous), (S)-(-)-1,1′-binaphthyl-
2,2′-diamine (≥98%, anhydrous), Human serum albumin (lyophilized powder, >97%, agarose gel 
electrophoresis) and morpholino propanesulfonic acid (MOPS) buffer (BioXtra ≥99.5% titration) 
were purchased from Sigma Alderich Chemicals. NaOH electrolytic pellets and Methanol 
(≥99.9% anhydrous) were purchased from Fisher Scientific.  
2.1.2 Cell Lines 
The triple negative breast cancer cells were purchased from American Type Culture 
Collection in Manassas, VA.  HCC1806 is a basal like cell line that expresses the triple negative 
phenotype. Cell line was characterized as a grade 2 tumor derived from a 60 year old African 
American woman.   
2.1.3 Preparation of Stock Solutions 
30mM MOPS buffer solution at pH 7.4 was prepared in a 1 liter volumetric flask by 
dissolving 6.27g of MOPS buffer with distilled water and adjusted to pH 7.4 by supplying drop 
wise NaOH solution. A .25% stock solution of HSA was prepared by dissolving HSA into a 250mL 
volumetric flask and diluted with the previously prepared MOPS buffer solution refrigerated and 
allowed to equilibrate for a period of 48 hours. 1.0x10-3M stock solutions of R- and S-TFE were 
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prepared by dissolving TFE in 25mL of analytical grade methanol in a volumetric flask. The 
1.0x10-3M stock solutions of R- and S-BNA were prepared by dissolving BNA in 25mL of 
analytical grade methanol in a volumetric flask. Accurate determination of HSA concentrations 
were performed using UV-Visible absorbance with λ max values of 280nm and an extinction 
coefficient of 38,553M-1cm-1. 
2.1.4 Sample Preparation 
Varying amounts of R- and S-TFE and R- and S-BNA were added to a fixed concentration 
of HSA in 30mM MOPS buffer solution, pH 7.4. The vials were capped, hand shaken and allowed 
to equilibrate for approximately 1 hour to ensure the binding of TFE and BNA to HSA. All samples 
were then subject to further analysis. The influence of temperature on the binding and emission 
property of TFE-HSA and BNA-HSA complexes was also investigated. All pH measurements 
were validated with a Fisher Scientific AB15 pH meter. 
2.1.5 TFE and BNA Enantiomer Titration of TN Breast Cancer Cells 
Triple negative breast cancer cells were exposed to a known concentration of TFE and BNA 
enantiomers for a period of 24 hours. Prior to chemical treatment, the cells were washed with 2mL of 
phosphate buffered saline (PBS). The PBS was removed and 2mL of fresh media was added. Treated cell 
were then allowed to incubate for 24 hours at 37°C and 5% CO2. Treated cells were photographed at 10x 
and 20x magnification to observe any physical characteristics of cell death.  
2.2 Instrumentation 
2.2.1 Fluorescence Spectroscopy Studies 
The fluorescence studies of TFE-HSA and BNA-HSA complexes were carried out on a 
JASCO FP-8500 spectrofluorometer equipped with temperature control using a 1 cm quartz cell. 
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The light source is a 150W xenon lamp with emission and excitation slit width of 2.5nm with a 
scan speed of 200nm/min. The emission spectra was recorded from 285nm to 551nm while the 
excitation was ran at 280nm. Fluorescence data was collected for HSA in the absence and presence 
of various concentrations of R- and S-TFE.   
2.2.2 Fluorescence Anisotropy Studies 
The fluorescence anisotropy measurements studies were carried out on the same JASCO 
FP-8500 spectrofluorometer with an automated polarizer accessory. Parallel and perpendicular 
emission components were measured in L-format by excitation at 295 nm from a 150-W xenon 
lamp. With each anisotropy measurement the parallel and perpendicular intensity of the 
background buffer solution was subtracted from the measured values of the sample. Anisotropy 
was measured three times at each titration point and the resulting anisotropy values were 
averaged.  
2.2.3 UV Absorption Studies 
The UV spectra was recorded with a Shimadzu UV-3600 NIR Spectrophotometer. 
Wavelength range began at 190 to 550nm with a fast scan speed. Sampling interval were set to 
5nm while measuring in absorbance and slit width set to 2.0nm. 
2.2.4 Fourier Transform Infrared Spectroscopy Studies 
FTIR studies were obtained by a Shimadzu IR Affinity-1 FTIR spectrophotometer. All 
samples were obtained ATR accessory under % transmittance with 100 scans. Wavenumber range 
from 700cm-1 to 1400cm-1.  
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CHAPTER 3 
RESULTS 
3.1 UV Spectra of HSA  
 
Figure 15. Uv-Vis Absorbance spectra of HSA 
The UV-Vis absorbance of HSA was taken to obtain an approximate concentration of the 
protein. Literature places the λ max of HSA at 280nm with a ε coefficient of 38553 Lmol-1cm-1. 
Figure 15 shows the UV-Vis absorption spectra of 2.7x10-5M of HSA in 30mM MOPS buffer at 
pH 7.4. The effects of temperature on the absorption spectra of HSA is shown below in figure 
15. Increasing temperatures lead to a decrease in the intrinsic absorption of HSA due to the 
denaturing of the proteins tertiary structure.  
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Figure 16. Effects of Temperataure on HSA Absorbance 
3.2 Effects of Temperature on HSA Fluorescence  
HSA has a major binding site that involves the lone tryptophan residue (Trp-214) which 
attributes to its intrinsic maximum fluorescence at 335nm. Tryptophan emission was monitored 
over five increasing temperatures 25, 37, 45, 55 and 65° Celsius.  
 
Figure *17. Influence of temperature on Fluorescence Spectra of HSA  
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Similar to its absorbance the fluorescence intensity of HSA decreased with the increase of 
temperature.  
3.3 FTIR Spectra of HSA and R- and S- TFE 
 
Figure *18. FTIR spectra of pure HSA, R- and S-TFE 
As stated previously, HSA is a large complex protein so it is expected to see amide peaks 
at approximately 1645 and 1521cm-1 corresponding to the C= O stretching and N-H bending 
respectively. Also seen is a broad peak at 3327cm-1 attributed by overlaid N-H stretching and O-
H stretching. The spectra of R- and S-TFE both exhibit peaks around 3300 cm-1 from O-H 
stretching and aromatic C=C bending around 1600-1500 cm-1. The spectra’s are expected to look 
identical due to the fact that enantiomers exhibit the same physical and spectral properties. 
 
 
Amide 1 Amide 2 
N-H 
Aromatic 
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3.4 FTIR Spectra of HSA and R- and S- BNA 
 
Figure 17. FTIR Spectra of pure HSA, R- and S- BNA 
As stated previously, HSA is a large complex protein so it is expected to see amide peaks 
at approximately 1645 and 1521cm-1 corresponding to the C= O stretching and N-H bending 
respectively. Also seen is a broad peak at 3327cm-1 attributed by overlaid N-H stretching and O-
H stretching. The spectra of R-and S-BNA exhibits two intense peaks at 3381 and 3473cm-1 due 
to its amine groups present as well as aromatic C=C bending around 1600-1500 cm-1. The 
spectra’s are expected to look identical due to the fact that enantiomers exhibit the same physical 
and spectral properties. 
 
 
 
Aromatic 
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3.5 Fluorescence Spectra of Enantiomers of HSA-TFE  
The fluorescence studies of HSA emission was performed at 25 37, 45, and 55 °C to later 
examine the thermodynamic properties associated with the TFE-HSA complexes. HSA 
concentration was fixed at 2.7x 10-6 M while varying the concentrations of R- and S-TFE from 
2.0x10-7 to 2.0x10-5µM.  
 
Figure 18. Fluorescence Spectra of R-TFE-HSA solution at 37 °C with concentrations ranging 
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm 
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Figure 19. Fluorescence Spectra of S-TFE-HSA solution at 37 °C with concentrations ranging 
from 2.0x10-6 to 7.0x10-6M at  pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm 
 
In the case of both enantiomers the addition of TFE leads to a decrease in fluorescence 
intensity of HSA at the λ max, indicating R- and S-TFE as quenching agents. We can also 
conclude that the increase of TFE concentration simultaneously decreases the fluorescence 
intensity while a slight blue shift is observed after reaching higher temperatures (a characteristic 
common to that of static quenching). Another region of interest is the emission at a longer 
wavelength that corresponds to TFE emission with a λ max of 417nm.Compared with tryptophan 
residue in HSA, TFE is more conjugated and is expected to emit at a longer wavelength. Increase 
in TFE concentration in HSA samples resulted in increased fluorescence intensity at the TFE 
region. In contrast the formation of TFE-HSA complex reduces the fluorescence intensity of TFE 
and is only further reduced by increasing temperatures. Additionally noted is the presence of an 
isobestic point around 338nm both R-and S-TFE.  The profiles of R- and S-TFE look identical so 
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an overlay of the emission of R- and S-TFE is plotted against concentration to obtain a more 
accurate observation and differences in emission properties of R- and S-TFE complexes. 
 
Figure 20. Overlaid emission of  R-TFE-HSA and  S-TFE-HSA Complexes 
 
Figure 23 shows that despite identical concentrations and being exposed to the exact 
same parameters there is still clear discrimination between the two enantiomers. The S 
configuration leads to a larger florescence decrease than its R enantiomer.  
3.6 Fluorescence Spectra of Enantiomers of HSA-BNA-Complexes 
The fluorescence studies using BNA as the chiral compound were performed identical to TFE 
complex samples. Samples were ran at 25 37, 45, and 55 °C with HSA concentration  fixed at 2.7x 10-
6 M while varying the concentrations of R- and S-BNA from 2.0x10-7 to 2.0x10-5µM.  
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Figure 21. Fluorescence Spectra of R-BNA-HSA solution at 37 °C with concentrations ranging 
from 2.0x10-6 to 7.0x10-6M at pH 7.4 Emission spectra= 285-551nm, Excitation=280nm 
 
 
Figure 22. Fluorescence Spectra of S-BNA-HSA solution at 37 °C with concentrations ranging 
from 2.0x10-6 to 7.0x10-6M at  pH 7.4 Emission spectra= 285-551nm, Excitation= 280nm 
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Similar to that of HSA-TFE complexes the addition of both enantiomers of BNA leads to 
the decrease in fluorescence intensity of HSA emission resulting in BNA also being a 
quenching agent. We can also note that the increase of BNA concentration simultaneously 
decreases the fluorescence intensity of HSA. Another region of interest is that of the BNA 
region. Additionally noted is the presence of an isobestic point around 373nm both R-and S-
BNA.  
We can also conclude that the increase of BNA concentration simultaneously decreases 
the fluorescence intensity. However unlike TFE, BNA showed no signs of spectral shift with 
increasing temperatures or concentration. The profiles of R- and S-TFE look identical so an 
overlay of the emission of R- and S-TFE is plotted against concentration to obtain a more 
accurate observation. 
 
 
 
Figure 23. Overlaid emission of  R- and  S-BNA Complexes 
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Figure 26 shows that despite identical concentrations and being exposed to the exact 
same parameters there is still clear discrimination between the two enantiomers. The S 
configuration leads to a larger florescence decrease than its R enantiomer.  
3.7 Determination of Binding Constant and Stoichiometry of R- and S-TFE-HSA 
Complexes 
When smaller molecules bind to large complex proteins at equivalent sites the 
equilibrium between the two can be evaluated using a modified Stern-Volmer equation shown 
below. 
 
log (
𝐹0−𝐹
𝐹
) = log K + nlog [TFE]  ...................................................................................... Equation 9 
 
Where K is the binding association constant to a particular site and n is molar ratio of 
TFE to HSA. F0 and F represent the fluorescent intensity before and after the addition of TFE 
respectively. This linear equation can be utilized by plotting the log [TFE] against the log of the 
change in fluorescence intensity.  
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Figure 24. Stern Volmer plot of R-TFE-HSA Complexes 
 
 
Figure 25. Stern Volmer plot of S-TFE-HSA Complexes 
 
From the slope and intercept of figures 20 and 21 the binding constant and stoichiometric 
ratios are shown in the table 2 below. 
Table 2. Binding & Stoichiometric Parameters of HSA-R and S-TFE 
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Based on our calculations the binding of TFE to HSA takes place at one site. However 
the binding constants differ significantly. This only further validates the importance chirality 
plays in protein-drug selection. At physiological temperatures the affinity of R-TFE to HSA is 
thirty-seven times higher than its S enantiomer while increasing temperatures only enhance the 
ratio. 
3.8 Determination of Binding Constant and Stoichiometry of R- and S-BNA-HSA 
Complexes 
Determination of binding constant and stoichiometry of R- and S-BNA-HSA was also 
evaluated by equation 9. This linear equation can be utilized by plotting the log [BNA] against 
the log of the change in fluorescence intensity. 
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Figure 26. Stern Volmer plot of R-BNA-HSA Complexes 
 
Figure 27. Stern Volmer plot of S-BNA-HSA Complexes 
From the slope and intercept of figures 20 and 21 the binding constant and stoichiometric 
ratios are shown in the table 2 below. 
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Table 3. 
 Binding & Stoichiometric Parameters of HSA-R and S-BNA 
 
 
 
Based on our calculations the binding of BNA to HSA takes place at one site. Likewise to 
TFE the binding constants differ significantly. At physiological temperatures the affinity of R-
BNA to HSA is one hundred and thirty times higher than its S enantiomer while increasing 
temperatures only enhance the ratio. 
3.9 Steady State Anisotropy Measurements 
Steady state anisotropy measurements were done to further explore chiral discrimination 
by monitoring its change in rotational diffusion.  
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Figure 28. Overlaid Anisotropy values Spectra of R- and S-TFE-HSA Complexes 
Sample preparation was similar to steady state fluorescence experiments above and the 
experiment was ran in triplicates. 27µM bovine serum albumin (BSA) in buffer solution was 
subject to anisotropy experiments to serve as preliminary experiments. The anisotropy values of 
BSA is initially increased upon binding to R-TFE while initial decreasing is observed in S-TFE 
complexes. Although the values show a type of erratic pattern you can still observe the 
enantiomers are always opposite to one another. As TFE concentration approaches that of BSA 
the anisotropy values becomes approximately back to that of its unbound state. In these 
experiments the change in anisotropy values correspond to the binding of the drug to the protein 
and at the drugs highest concentration (20µM) the anisotropy exhibits values similar to its 
unbound state indicative of no interaction between the drug and the protein.  
3.10 Thermodynamic Properties of Enantiomer of TFE-HSA Complexes 
Small molecules can bind independently to large proteins at equivalent sites and they can 
do so by four possible binding modes: hydrogen bonds, van der Walls forces, ionic interactions, 
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or hydrophobic interactions. Thermodynamic parameters are essential for determining the 
driving force of chemical reactions thus this study was performed at four different temperatures 
to better understand the driving force associated with the binding of TFE to HSA.  
The Van’t Hoff equation (equation 12) and the Gibbs free energy equation (equation 11)  
shown below can be applied to aid in determining these parameters.38   If  the reaction equation is 
at equilibrium the following relationship can be said.  
∆G = -RT ln K ................................................................................................................ Equation 10 
 
Where ∆G is the Gibbs free energy, R is the gas constant and K is the binding constants 
calculated previously at a specific temperature (T). Rearranging the equation to solve for the 
natural log and replacing ∆G with its equality in equation 11, we arrive to the linear Van’t Hoff 
equation.  
∆G=∆H-T∆S .................................................................................................................. Equation 11 
 
ln K= 
−∆𝐻
𝑅𝑇
+  
∆𝑆
𝑅
 .............................................................................................................. Equation 12 
Where K is the binding constant discovered earlier at the temperature (T) indicated and R 
is the gas constant. A plot of the inverse temperature against the ln K is produced and the slope 
and intercept are used to calculate enthalpy (ΔH) and entropy (ΔS) associated with the complex 
formation of R- and S-TFE-HSA complexes at a specific temperature. The Gibbs free energy can 
then be estimated by using equation 11.39 
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Figure 29. Van’t Hoff plot of R-TFE-HSA Complexes 
 
 
Figure 30. Van’t Hoff plot of S-TFE-HSA Complexes 
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Table 4.  
Thermodynamic parameters of R- and S-TFE-HSA Complexes 
 
The negative values of ∆G shown for R- and S-TFE reveals that the interactions between 
both enantiomers of TFE and HSA are in fact spontaneous. Ross and Subramanian40 have 
constructed a graph that correlates the sign and magnitude of the thermodynamic parameters to 
the various types of interactions that can take place in protein-ligand binding. 
Table 5.  
Expected signs of controbutions to ∆H and ∆S 40 
Process ∆H ∆S 
Hydrophobic + + 
Van der Walls - - 
H-Bonding - - 
Ionic Slight + or - + 
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In the case of HSA binding to R- and S-TFE the positive ∆H and ∆S values correspond to a high 
possibility of hydrophobic interactions.  
3.11 Thermodynamic Properties of Enantiomer of BNA-HSA Complexes 
Similar to that of TFE-HSA diastereomic complexes, the relationship between equations 
10 and 11 were used to obtain the linear Van’t Hoff equation and from the slope and intercept are 
the values found in table 6. 
 
Figure 31. Van’t Hoff plot of R-BNA-HSA Complexes 
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Figure 32. Van’t Hoff plot of S-BNA-HSA Complexes 
Table 6.  
Thermodynamic parameters of R- and S-BNA-HSA Complexes 
 
The negative values of ∆G shown for S-BNA and positive values of R-BNA reveal that the 
interactions between one enantiomer is favored while the other is not. 
 
  
50 
 
3.12 Enantiomeric Cytotoxicity on Triple Negative Breast Cancer Cells  
Preliminary cell cytotoxicity studies were conducted on triple negative breast cancer cells to 
observe any discriminatory differences by enantiomers of TFE and BNA. Cell viability was taken 24 
hours after exposure to known concentrations of both TFE and BNA enantiomers. Figures 36 through 42 
is the microscopic view of the effects of TFE and BNA enantiomers on triple negative breast cancer cells 
at 10x magnification after 24 hour exposure.  
 
                               
Figure 33. Pretreatmnent 10x                                           Figure 34. No Treatment 10x 
                               
                   
 
 
Figure 35. Methanol Control 10x                                     
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Figure 36. S-BNA Treatment 10x                                    Figure 37. R-BNA Treatmeant 10x 
                           
  
                               
Figure 38. S-TFE Treatment 10x                                     Figure 39. R-TFE Treatment 10x 
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CHAPTER 4 
DISCUSSION 
4.1 Determination of Binding Constant and Stoichiometry of Enantiomers of HSA-TFE 
Referring to Table 2, clear chiral discrimination is observed during the binding of R-TFE 
to HSA and S-TFE to HSA. Both enantiomers exhibit the same stoichiometric ratio to the 
protein. However despite identical chemical composition of the compounds, HSA is still able to 
discriminate between the two enantiomers. Both enantiomers exhibit stronger affinity with 
increasing temperature even though R-TFE complexes show an affinity eight times higher than 
S-TFE.   
4.2 Determination of Binding Constant and Stoichiometry Enantiomers of HSA-BNA 
Despite differences in the structure and chemical composition of TFE and BNA, the 
binding interactions of BNA enantiomers to HSA further proves chiral discrimination. The 
binding of R- and S-TFE to HSA has one binding site. However, the spatial arrangement of the 
enantiomers is allowing them to interact differently with the protein. In contrast to TFE 
diastereomer complexes, increasing temperatures decrease binding affinity for the S 
configuration.  
4.3 Thermodynamic Properties of Enantiomer of HSA-TFE Complexes 
Referencing Table 4, at physiological temperatures the interaction between both R- and 
S-TFE is determined favorable by its ∆G value. The enthalpy change associated with the R 
enantiomer is almost three times higher than its S enantiomer. This could be a result of higher 
binding affinity. In both cases the disorder in the system is miniscule in comparison to its 
enthalpy value, however the ∆S values differ significantly between the two enantiomers. The ∆S 
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is two times higher in R-TFE than in S-TFE. Based on the signs and magnitudes of the calculated 
thermodynamic parameters the binding interactions are largely contributed by hydrophobic 
interactions.40 These interaction could be possible by potential unfolding of the protein to allow 
TFE to enter into a hydrophobic region on the protein. However, other factors including 
hydrogen bonding and electron transfer may also facilitate the TFE-HSA complex formation. 
Some principle binding sites on HSA are noted to have large hydrophobic cavities however the 
literature suggest typical ligands for this site are bulky heterocyclic  molecules and the 
interactions to be electrostatic. Further research must be conducted to obtain an approximate 
binding mechanism.  
4.4 Thermodynamic Properties of Enantiomer of HSA-BNA Complexes 
Referencing Table 6, at physiological temperatures the interaction between S-BNA is 
favorable however its R-enantiomer is not. These values raise concern when examining the 
higher binding constant shown for the R-enantiomer. Another interesting observation is the 
different signs for the disorder and enthalpy in the system of R- and S-TFE. A negative value for 
∆S indicates the disorder involved in the interaction of S-BNA and HSA is lowered upon 
binding. However this R-BNA-HSA complex also exhibits and negative H values indicating that 
the reaction is exothermic and possibly driven by enthalpy. The negative values for both ∆S and 
∆H indicate the major mode of binding is due to hydrogen bonds and van der Walls forces. This 
BNA complex has four hydrogen atoms on its exterior that can assist in hydrogen bonding to and 
van der Wall forces to the positively charges side chains of the amino acids in the protein.  
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4.5 Cell Viability and Cytotoxicity Studies 
Preliminary studies at concentration 3.0X10-5M, show clear morphology effects in the 
presence of TFE and BNA enantiomers. From the differences of S-BNA and R-BNA in Figures 
39 and 40 respectively, the R-BNA shows a qualitative difference in cell viability. In contrast to 
BNA enantiomers S-TFE shows the qualitative difference in cell viability. Something of 
immediate interest was the relationship between the K values and the observations during cell 
viability. Our BNA enantiomers which showed higher binding constants where able to penetrate 
the cells more than the TFE enantiomers. Cell viability experiments are still currently being 
optimized for each compound. 
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CHAPTER 5 
CONCLUSION 
This work successfully utilized Fluorescence, UV-visible and Fourier transform infrared 
spectroscopy to shows the chiral discrimination between two different chiral environmental 
pollutants, S (-), R (+) 1- (9-anthryl) - 2, 2, 2- triflouroethanol (TFE) and (R)-(+), (S)-(-)-1,1′-
binaphthyl-2,2′-diamine (BNA) in solution with human serum albumin as the chiral selector. 
This study shows that both compounds act as a quencher of intrinsic HSA fluorescence and do so 
by static quenching. From the quenching studies we were able to determine the binding 
constants, stoichiometry and, thermodynamic parameters of binding to HSA. This work also 
began to explore the mobility and cytotoxicity of our compounds.  
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